Regado Biosciences
Durham
About Regado Biosciences
Regado Biosciences is a biopharmaceutical company, engages in the discovery and development of aptamer-based antidote-controlled therapeutics. It provides REG1 that is used in patients suffering from acute coronary syndrome who undergo coronary revascularization procedures, which include coronary artery bypass grafting and percutaneous coronary intervention. It was founded in 2001 and headquartered in Durham, North Carolina.
Company Facts
- Operating status: Active
- Company type: For Profit
- IPO status: Delisted
- Employees: 11 – 50
- Total funding: $154.0M
- Funding stage: M&A
- Last round: Post-IPO Equity (Jan 2014)
- Ticker: nasdaq:RGDO
- Website: regadobiosciences.com
- Phone: 19083250239
Industries & Categories
Biotechnology, Health Care, Therapeutics
Canonical: https://fsome.com/organization/regado-biosciences-1812908 · For the full interactive profile (charts, investors, team, acquisitions, press), please enable JavaScript.